GMP FirstEnergy Maintains a Buy Rating on HLS Therapeutics Inc (HLS)

By Ryan Adsit

In a new note to investors on August 9, an analyst has provided a rating update for HLS Therapeutics Inc (HLSResearch Report). The Healthcare company, HLS Therapeutics Inc (TSX: HLS) has received a rating update from a Wall Street analyst on August 9.

According to, Keywood is ranked #3420 out of 5239 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HLS Therapeutics Inc with a C$22 average price target.

HLS Therapeutics, Inc. operates as a pharmaceutical company. It focuses on the acquisition and commercialization of late-stage development, commercial-stage promoted and established, branded pharmaceutical products in the North American markets.

The company’s shares closed last Tuesday at C$15.20.